CD40 and pancreatic ductal adenocarcinoma: It was reported that CD40 agonists can mediate tumor regression in pancreatic ductal adenocarcinoma in mice and patients [26], in which the underlying immune mechanism can be both T-cell-dependent and T-cell-independent.